Mode of delivery of HIV-infected women: a retrospective study of 358 pregnancies followed in the same hospital between 2000 and 2004;Accouchement des patientes enceintes infectées par le VIH : étude rétrospective de 358 grossesses suivies entre 2000 et 2004

Gynecologie Obstetrique et Fertilite

Volumn 34, Issue 4, 2006, Pages 304-311

  Rodrigues, A ^a   Faucher, P ^a   Batallan, A ^a   Allal, L ^a   Legac, S ^a   Matheron, S ^a   Madelenat, P ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Caesarean; HAART; HIV; Mother to child transmission; Pregnancy

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTICLE; BIRTH; DELIVERY; DISEASE TRANSMISSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; FETUS; FOLLOW UP; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INTRAUTERINE INFECTION; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MATERNAL CARE; MATERNITY WARD; MEDICAL DECISION MAKING; MONOTHERAPY; MOTHER FETUS RELATIONSHIP; NEWBORN CARE; PREGNANCY DISORDER; PREMATURITY; STILLBIRTH; TWIN PREGNANCY; VAGINAL DELIVERY; VIRUS DETECTION; VIRUS LOAD; VIRUS TRANSMISSION; CESAREAN SECTION; METHODOLOGY; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; RETROSPECTIVE STUDY; RISK FACTOR;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CESAREAN SECTION; DELIVERY, OBSTETRIC; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD; ZIDOVUDINE;

EID: 33646178992     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2006.01.039     Document Type: Article

References (31)

1. ® prophylaxis and mode of delivery in the French perinatal cohort. JAMA 280 (1998) 55-60
2. The European mode of delivery collaboration. Elective caesarean section vs vaginal delivery in preventing vertical HIV-1 transmission: a randomised clinical trial. Lancet 353 (1999) 1035-1039
3. The International Perinatal HIV group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus Type 1: a meta-analysis of 15 prospective cohort studies. N. Engl. J. Med. 340 (1999) 977-987
4. ®. Pediatric AIDS clinical trials group study 185 teams. N. Engl. J. Med. 341 6 (1999) 385-393
5. Garcia P.M., Kalish L.A., Pitt J., Minkoff H., Quinn T.C., Burchett S.K., et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and infants transmission study group. N. Engl. J. Med. 341 6 (1999) 394-402
6. The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 13 11 (1999) 1377-1385
7. Ioannidis J.P., Abrams E.J., Ammann A., Bulterys M., Goedert J.J., Gray L., et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000 copies/ml. J. Infect. Dis. 183 4 (2001) 539-545
8. Cooper E.R., Charurat M., Mofenson L.M., et al. Combination antiretroviral strategies for women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr. 29 484 (2002) 94
9. Morris A.B., Dobles A.R., Cu-Uvin S., Zorrilla C., Anderson J., Harwell J.I., et al. Protease inhibitor use in 233 pregnancies. J. Acquir. Immune Defic. Syndr. 40 1 (2005) 30-33
10. Rowland B.L., Vermillion S.T., and Soper D.E. Scheduled cesarean delivery and the prevention of human immunodeficiency virus transmission: a survey of practicing obstetricians. Am. J. Obstet. Gynecol. 185 327 (2001) 31
11. Stringer J.S.A., Rouse D.J., and Goldenberg R.L. Prophylactic cesarean delivery for the prevention of perinatal human immunodeficiency virus transmission: the case for restraint. JAMA 281 (1999) 1946
12. Delfraissy J.F. Pour les groupes d'experts cliniciens et virologues : prise en charge thérapeutique des personnes infectées par le VIH (2004), Flammarion, Paris France
13. Mandelbrot L., Kermarrec N., Marcollet A., Lafanechère A., Longuet P., Chosidow D., et al. Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. AIDS 17 2 (2003) 272-273
14. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 40 3 (2005) 458-465
15. Données disponibles sur le site de l'EPF :http://u569.kb.inserm.fr/epfbiblio/index.htm.
16. Dorenbaum A., Cunningham C.K., Gelber R.D., Culnane M., Mofenson L., Britto P., et al. International PACTG 316 team. Two-dose intrapartum-newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 288 2 (2002) 189-198
17. Public health service task force perinatal HIV guidelines working group. Summary of the updated recommendations from the public health service task force to reduce perinatal human immunodeficiency virus-1 transmission in the United States. Obstet. Gynecol. 99 6 (2002) 1117-1126 (Review)
18. Louis J.M., Buhari M.A., Blackwell S.C., Refuerzo J., Allen D., Gonik B., et al. Characteristics associated with suboptimal viral suppression at delivery in human immunodeficiency virus-1-infected pregnant women. Am. J. Obstet. Gynecol. 193 3 Pt 2 (2005) 1266-1269
19. Peters V.B., Liu K.L., Dominguez K.L., et al. Missed opportunities for perinatal HIV prevention among HIV-exposed infants born 1996-2000, pediatric spectrum of HIV disease cohort. Pediatrics 111 (2003) 118691
20. Cliffe S., Tookey P.A., and Nicoll A.G. Antenatal detection of HIV: national surveillance and unlinked anonymous survey. BMJ 323 (2001) 3767
21. Mayaux M.J., Teglas J.P., Blanche S., and French pediatric HIV infection study group. Characteristics of HIV-infected women who do not receive preventive antiretroviral therapy in the French perinatal cohort. J. Acquir. Immune Defic. Syndr. 34 3 (2003) 338-343
22. Rakhmanina N.Y., van den Anker J.N., and Soldin S.J. Safety and pharmacokinetics of antiretroviral therapy during pregnancy. Ther. Drug Monit. 26 2 (2004) 110-115 (Review)
23. Watts D.H., Lambert J.S., Stiehm E.R., Bethel J., Whitehouse J., Fowler M.G., et al. Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of < or = 500/microliter. Am. J. Obstet. Gynecol. 183 1 (2000) 100-107
24. Marcollet A., Goffinet F., Firtion G., Pannier E., Le Bret T., Brival M.L., et al. Differences in postpartum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery. Am. J. Obstet. Gynecol. 186 4 (2002) 784-789
25. Read J.S., Tuomala R., Kpamegan E., Zorrilla C., Landesman S., Brown G., et al., Women and infants transmission study group. Mode of delivery and postpartum morbidity among HIV-infected women: the women and infants transmission study. J. Acquir. Immune Defic. Syndr. 26 3 (2001) 236-245
26. Rodriguez E.J., Spann C., Jamieson D., and Lindsay M. Postoperative morbidity associated with cesarean delivery among human immunodeficiency virus-seropositive women. Am. J. Obstet. Gynecol. 184 6 (2001) 1108-1111
27. Fiore S., Newell M.L., Thorne C., and European HIV in obstetrics group. Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery. AIDS 18 6 (2004) 933-938
28. International perinatal HIV group duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS 15 3 (2001) 357-368
29. Van Dyke R.B., Korber B.T., Popek E., and Macken C. The ariel project: a prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J. Infect. Dis. 179 2 (1999) 319-328
30. Mrus J.M., Goldie S.J., Weinstein M.C., and Tsevat J. The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy. AIDS 14 16 (2000) 2543-2552
31. Read J., and Newell M. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst. Rev. 4 (2005) 1-14